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Abstract As a continued effort to develop multivalent
ligands to enhance the pharmacological effects of mono-
meric drugs, DITC-APEC, a chemically reactive nucleo-
side A2A adenosine receptor (AR) agonist, was employed to
derivatize the surface of third-generation (G3) polyamido-
amine (PAMAM) dendrimers. The resulting conjugates
carried multiple copies of the agonist attached through a
thiourea linkage and differed in the number of attachments
and in the presence of a fluorophore or additional surface
modification. Computer modeling studies suggested that
these DITC-APEC-loaded dendrimers extended the overall
diameter of the previously reported PAMAM-CGS21680
dendrimer derivatives (Kim et al., Bioconjugate Chem 2008
19:406–411) by ca. 20 Å, potentially increasing the
conformational flexibility of the appended ligands to achieve
optimal geometry for efficient binding at A2A ARs. Increased
affinity and selectivity in binding in comparison to the
CGS21680 conjugate were envisioned, due to the presence
of an extended linker, i.e., a dithioureylenephenyl function-
ality. In vitro radioligand competition experiments showed
effective binding of these PAMAM-DITC-APEC dendrimer
conjugates at the human A2A and A3 ARs with submicro-
molar Ki values and selectivity in comparison to the human
A1 AR. Furthermore, these nucleoside-loaded dendrimers
exhibited an A2A AR-mediated inhibitory effect on ADP-
induced aggregation of human platelets. The present study
demonstrates the potential of applying the functionalized
congener concept to engineer dendrimer-based multivalent
ligands for G protein-coupled receptors.
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ADP Adenosine 5′-diphosphate
APEC 2-[4-(2-Aminoethylaminocarbonylethyl)
phenylethylamino]-5′-N-ethylcarboxamidoa-
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AR Adenosine receptor
Boc Tert-butoxycarbonyl
CHO Chinese hamster ovary
COSY Correlation spectroscopy
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Seoul 136-791, KoreaCGS21680 2-[4-(2-Carboxylethyl)phenylethylamino]-
5′-N-ethylcarboxamidoadenosine
DIEA N,N-diisopropylethylamine
DITC-APEC 4-Isothiocyanatophenylaminothiocarbonyl-
APEC
DMF N,N-dimethylformamide
DMSO Dimethyl sulfoxide
ED Ethylenediamine
GPCR G protein-coupled receptor
HEK Human embryonic kidney
NMR Nuclear magnetic resonance
NOESY Nuclear Overhauser enhancement
spectroscopy
PAMAM Polyamidoamine
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophospho-
nium hexafluorophosphate
SCH442416 5-Amino-7-(3-(4-methoxy)phenylpropyl)-2-
(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,
5-c]pyrimidine
SEC Size exclusion chromatography
Introduction
Ligand interactions with cell-surface receptors, such as
GPCRs, are employed to modulate cellular functions for the
treatment of diseases. An example of this strategy is to
develop high-affinity synthetic ligands with enhanced
potency and receptor selectivity. In addition to the classical
medicinal chemical approach of structural modification of
small monomeric drugs, one way to achieve higher binding
affinity and selectivity of a given ligand for its receptor is to
anchor multiple copies of the ligand to a single macromo-
lecular carrier such as a dendrimer [1–4].
Dendrimers have a treelike macromolecular architecture
which are prepared through iterative organic synthesis and
can serve as nanocarriers for drug delivery [5–7]. Due to its
well-defined chemical structure, the dendrimer carrier may
display more consistent biological effects than conventional
polymeric drug delivery systems, such as vinyl polymers,
polysaccharides, synthetic poly(α-amino acids), and poly
(ethylene glycol). Furthermore, its globular shape may
improve the pharmacokinetic properties of a bound drug
[1]. The anticipated cooperative effect from simultaneous
multivalent ligand-receptor binding mediated by a single
dendritic scaffold may impart additional affinity and
selectivity in a manner not possible using small molecules
[8]. Given the appropriate geometry, a multivalent effect
could take advantage of complex assemblies of GPCRs or
clustering that may be present on the cell surface [9].
The functionalized congener approach, originally intro-
duced for GPCR drug design, involves structural variation at
the distal unit of a pre-existing ligand in order to improve its
pharmacological effects [10, 11]. The key pharmacophore
unit of a small molecular ligand for a GPCR generally binds
within its heptahelical transmembrane domain [12, 13]. In
the case of functionalized congeners, the distal chemical
functionality of an appended chain may reside and poten-
tially interact at/near the extracellular domain of the GPCR.
Indeed, improving this secondary interaction can significant-
ly enhance the affinity and selectivity of certain ligands.
Such modulation of the pharmacological profile can be
achieved at the distal unit through a variation of the linker
length, functional group manipulation, or a combination of
both techniques.
The A2A adenosine receptor (AR) is one of the four
known AR subtypes relevant to various diseases including
thrombosis, inflammation, nervous system disorders, and
ischemia reperfusion damage [14–16]. Recently, we have
reported using a dendritic scaffold to load multiple copies of
the A2A AR agonist, CGS21680 4, to create a macromolec-
ular drug carrier system [17]. Here, in an effort to expand the
development of dendrimer-based multivalent ligands for
GPCRs, we have incorporated DITC-APEC 2 [18–20]t o
the surface of a third-generation (G3) PAMAM dendrimer 6
[21] by forming a thiourea linkage. Previously, DITC-APEC,
an A2A AR-specific agonist, was shown to irreversibly
activate the AR signaling pathway through covalent attach-
ment at the extracellular domain of the receptor [18, 19]. The
present study demonstrates the application of the function-
alized congener approach to polyvalent ligand design.
Materials and methods
Glassware was oven-dried and cooled in a desiccator before
use. All reactions were carried out under a dry nitrogen
atmosphere. Solvents were purchased as anhydrous grade
and used without further purification. Suppliers of the
commercial compounds are as follows: amine-terminated
G3 PAMAM dendrimer with an ethylenediamine core,
acetic anhydride (Ac2O), N-(2-aminoethyl)acetamide, tri-
ethylamine, N,N-diisopropylethylamine (DIEA), dimethyl
sulfoxide (DMSO), acetonitrile (CH3CN), methanol
(MeOH), chloroform (CHCl3), and isopropanol were
purchased from Aldrich; N,N-dimethylformamide (DMF)
was purchased from Acros; DMSO-d6 was purchased from
Cambridge Isotope Laboratories; 5-carboxyfluorescein suc-
cinimidyl ester was purchased from Invitrogen; 2-[4-(2-
aminoethylaminocarbonylethyl)phenylethylamino]-5′-N-
ethylcarboxamidoadenosine (APEC) bistrifluoroacetic acid
was provided by NIMH Chemical Synthesis and Drug
Supply Program. Radioligands were purchased from Perkin
Elmer Life and Analytical Science.
Thin-layer chromatography (TLC) was performed on
0.2 mm silica glass coated sheets (E. Merck) with F-254
40 Purinergic Signalling (2009) 5:39–50indicator. Visualization of the products on TLC plates was
performed by UV light, potassium permanganate, or iodine.
Preparative SEC was performed on Bio-Beads® S-X1 beads
(BIO-RAD, MWoperating range from 600–14,000 Da), 200–
400 mesh, with DMF (Aldrich 99.8%, anhydrous) as an eluent
at ambient pressure.
NMR spectra were recorded on a Bruker DRX-600
spectrometer at 25.0°C under an optimized parameter
setting for each sample, unless otherwise mentioned.
1H
NMR chemical shifts were measured relative to the residual
solvent peak at 2.50 ppm in DMSO-d6. Complete NMR
peak assignments were made possible with 2D COSY and
NOESY experiments. For dendrimer conjugates, only the
peaks clearly resolved in the
1H NMR spectra were listed.
Since the MWof each dendrimer conjugate was determined
as the average value from its polymeric distribution and the
dendrimer structure was not unimolecular, the integration
value of each peak was reported to two decimal places as
determined by the
1H NMR analysis. A methylene peak of
PAMAM dendrimer near 2.20 ppm (“c”, see peak
labeling of 10) was used as an internal standard (set at
120 H) for the integration, assuming 32 peripheral groups
without any defects in the structure. Full peak assignments
of dendrimer conjugates are shown in the Supporting
Information.
The electrospray ionization (ESI) MS experiments were
performed on a Waters LCT Premier mass spectrometer at
the Mass Spectrometry Facility, NIDDK, NIH.
DITC-APEC 2 The synthesis of this compound was
reported previously [20] APEC 1 (54.0 mg, 70.2 μmol, as
a 2 TFA salt) and diisothiocyanatobenzene (40.0 mg,
208 μmol) were dissolved in a mixture of 1:1 CH3CN/
isopropanol (5 mL), and then triethylamine (100 μL,
718 μmol) was added to this mixture. The reaction was
stirred for 2 h at room temperature, the solvent was
removed in vacuo, and the crude product was purified by
preparative TLC (4:1 CHCl3/MeOH) to give 41.4 mg
(56.4 μmol, 80%) of 2 as a white solid. Prolonged reaction
time increased the amounts of side-products. Rf: 0.40 [silica
gel, 4:1 CHCl3/MeOH];
1H NMR (600 MHz, DMSO-d6) δ
9.80 (br s, 1H, H12), 8.04 (br s, 1H, H15), 8.02 (s, 1H,
H8Ad), 8.00 (s, 1H, H8), 7.92 (s, 1H, H11), 7.53 (d, 2H, J=
7.5 Hz, H14), 7.37 (d, 2H, J=7.4 Hz, H13), 7.15 (d, 2H, J=
8.3 Hz, H4/H5), 7.11 (d, 2H, J=7.8 Hz, H4/H5), 6.79 (br s,
2H, H6Ad), 6.20 (t, 1H, J=5.2 Hz, H1), 5.84 (d, 1H, J=
7.6 Hz, H1′), 5.58 (d, 1H, J=4.6 Hz, H3′-OH), 5.50 (d, 1H, J=
6.2 Hz, H2′-OH), 4.72 (dd, 1H, J=11.0, 6.0 Hz, H2′), 4.25 (d,
1H, J=2.4 Hz, H4′), 4.18 (m, 1H, H3′), 3.52 (m, 2H, H10),
3.49–3.34 (m, 2H, H2), 3.25 (q, 2H, J=6.1 Hz, H9), 3.20–
3.03 (m, 2H, H16), 2.77 (m, 4H, H3 and H6), 2.36 (t, 2H, J=
7.8 Hz, H7), 0.97 (t, 3H, J=7.1 Hz, H17); HRMS (ESI)
calculated for C33H40N11O5S2 (M+H
+): 734.2655, found:
734.2674.
APEC monomeric control 3 DITC-APEC 2 (5.26 mg,
7.17 μmol) was dissolved in DMSO-d6 (300 μL), and
triethylamine (20 μL, 144 μmol) was added to this solution.
N-Acetylethylenediamine (2.00 μL, 18.8 μL, 90% tech.)
was added to this stirred mixture. The reaction was stirred
for 16 h at room temperature. The solvent was removed in
vacuo, and the crude product was purified by preparative
TLC (5:2 CHCl3/MeOH) to give 0.89 mg (1.56 μmol,
22%) of 3 as a white solid. Low yield of this reaction could
be due to the highly polar nature of the desired compound
3, which was difficult to completely recover from the silica
gel. Rf: 0.25 [silica gel, 4:1 CHCl3/MeOH];
1HN M R
(600 MHz, DMSO-d6) δ 9.58 (br s, 2H, H12 and H15), 8.04
(br s, 1H, H21), 8.02 (s, 1H, H8Ad), 7.983 (s, 1H, H8/H19),
7.975 (s, 1H, H8/H19), 7.67 (br s, 2H, H11 and H16), 7.32 (s,
4H, H13 and H14), 7.16 (d, 2H, J=8.1 Hz, H4/H5), 7.11 (d,
2H, J=7.9 Hz, H4/H5), 6.80 (br s, 2H, H6Ad), 6.20 (t, 1H,
J=5.3 Hz, H1), 5.84 (d, 1H, J=6.8 Hz, H1′), 5.58 (d, 1H, J=
4.7 Hz, H3′-OH), 5.50 (d, 1H, J=6.2 Hz, H2′-OH), 4.72 (dd,
1H, J=11.3, 6.1 Hz, H2′), 4.25 (d, 1H, J=2.0 Hz, H4′), 4.18
(m, 1H, H3′), 3.51 (m, 4H, H10 and H17), 3.49–3.34 (m, 2H,
H2), 3.23 (m, 4H, H9 and H18), 3.20–3.03 (m, 2H, H22),
2.77 (m, 4H, H3 and H6), 2.35 (t, 2H, J=8.0 Hz, H7), 1.80
(s, 3H, H20), 0.97 (t, 3H, J=7.0 Hz, H23); HRMS (ESI)
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+): 836.3448, found:
836.3440.
CGS21680 monomeric control 5 CGS21680 4 (6.26 mg,
11.5 μmol, as a hydrochloride and hemihydrate salt) was
d i s s o l v e di nD M F( 1 . 0 0m L ) ,a n dD I E A( 9 . 1 5μL,
52.5 μmol) was added to this solution. Then N-acetylethy-
lenediamine (4.00 μL, 37.6 μmol) was added to the stirred
mixture, followed by PyBOP (5.41 mg, 10.4 μmol) in one
portion as a solid. The reaction was stirred for 18 h at room
temperature, the solvent was removed in vacuo, and the
crude product was purified by preparative TLC (5:1 CHCl3/
MeOH) to give 0.88 mg (1.51 μmol, 15%) of 5 as a white
solid. Low yield of this reaction could be due to the highly
polar nature of the desired compound 5, which was difficult
to completely recover from the silica gel. Rf: 0.28 [silica gel,
4:1 CHCl3/MeOH];
1H NMR (600 MHz, DMSO-d6) δ 8.04
(br s, 1H, H13), 8.02 (s, 1H, H8Ad), 7.87 (t, 1H, J=5.2 Hz,
H8), 7.83 (t, 1H, J=5.1 Hz, H11), 7.15 (d, 2H, J=7.8 Hz, H4/
H5), 7.11 (d, 2H, J=8.4 Hz, H4/H5), 6.79 (br s, 2H, H6Ad),
6.20 (t, 1H, J=5.3 Hz, H1), 5.84 (d, 1H, J=6.8 Hz, H1′), 5.58
(d, 1H, J=4.1 Hz, H3′-OH), 5.50 (d, 1H, J=6.3 Hz, H2′-OH),
4.72 (dd, 1H, J=11.7, 6.3 Hz, H2′), 4.25 (d, 1H, J=2.3 Hz,
H4′), 4.18 (m, 1H, H3′), 3.49–3.35 (m, 2H, H2), 3.20–3.04
(m, 2H, H14), 3.05 (m, 4H, H9 and H10), 2.76 (m, 4H, H3
and H6), 2.33 (t, 2H, J=8.1 Hz, H7), 1.78 (s, 3H, H12), 0.97
(t, 3H, J=7.3 Hz, H15); HRMS (ESI) calculated for
C27H38N9O6 (M+H
+): 584.2945, found: 584.3066.
PAMAM-DITC-APEC conjugate 10 A ca. 2.39 mM solu-
tion of 7 [22] in DMSO (560 μL, 1.34 μmol) was diluted
with DMSO (240 μL), and DIEA (10.0 μL, 57.4 μmol)
was added to this stirred solution. Subsequently, a 6.51 mM
solution of 5-carboxyfluorescein succinimidyl ester 8 in
DMSO (200 μL, 1.30 μmol) was slowly added. The
reaction was protected from light and stirred for 48 h at
room temperature to make 9. A portion of this crude
solution of 9 (480 μL, 0.643 μmol, ca. 1.34 mM) was
transferred into another flask, and a 44.1 mM solution of
DITC-APEC 2 in DMSO (130 μL, 5.73 μmol) was slowly
added to this stirred mixture. The reaction was stirred for
5 days protected from light, purified by SEC (H 36.5 cm×
O.D. 4.5 cm) in DMF, and dried in vacuo to give 10 as an
orange glassy solid.
1H NMR (600 MHz, DMSO-d6) δ
7.36, 7.32 (br s (each), 18.64H, H13 and H14), 7.14, 7.12 (d
(each), 20.89H, H4 and H5), 6.80 (br s, 9.36H, H6Ad), 6.20
(s, 5.07H, H1), 5.84 (d, 4.76H, J=6.2 Hz, H1′), 4.72 (m,
4.42H, H2′), 4.26 (s, 5.12H, H4′), 4.19 (s, 4.82H, H3′), 2.77
(m, 26.71H, H3 and H6), 2.64 (m, 120.47H, Hb and Hg),
2.42 (m, 51.65H, He and Ha), 2.35 (m, 17.48H, H7), 2.18
(m, 120.00H, Hc), 1.79 (s, 41.15H, Hh), 0.97 (t, 14.60H, J=
6.7 Hz, H18).
PAMAM-DITC-APEC conjugate 12 A ca. 2.68 mM solu-
tion of 6 in DMSO (270 μL, 0.724 μmol) was diluted with
DMSO (160 μL), and DIEA (10.0 μL, 57.4 μmol) was
added to this stirred solution. Subsequently, a 6.51 mM
solution of 5-carboxyfluorescein succinimidyl ester 8 in
DMSO (110 μL, 0.716 μmol) was slowly added. The
reaction was protected from light and stirred for 48 h at
room temperature to make 11. A portion of this crude
solution of 11 (250 μL, 0.335 μmol, ca. 1.34 mM) was
transferred into another flask, and a 44.1 mM solution of
DITC-APEC 2 in DMSO (350 μL, 15.4 μmol) was slowly
added to this stirred mixture. The reaction was stirred for
5 days protected from light, purified by SEC (H 39 cm×O.
D. 3.0 cm) in DMF, and dried in vacuo to give 12 as an
orange glassy solid.
1H NMR peak assignments were made
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1H NMR (600 MHz, DMSO-d6) δ 7.35, 7.32 (br s (each),
113.53H, H13 and H14), 7.14, 7.10 (d (each), 117.93H, H4
and H5), 6.81 (br s, 48.03H, H6Ad), 6.19 (s, 29.61H, H1),
5.85 (d, 29.58H, J=6.6 Hz, H1′), 5.63, 5.57 [br s (each),
52.70H, H3′-OH and H2′-OH], 4.73 (m, 27.32H, H2′), 4.26 (s,
30.11H, H4′), 4.19 (s, 27.26H, H3′), 3.24 (m, 119.79H, H9
and HfAPEC), 2.77 (m, 120.73H, H3 and H6), 2.66 (m,
90.20H, Hb), 2.43 (m, 46.27H, He and Ha), 2.35 (m,
72.28H, H7), 2.21 (m, 120.00H, Hc), 0.96 (t, 92.42H, J=
6.9 Hz, H18).
PAMAM-DITC-APEC conjugate 13 A ca. 2.68 mM solu-
tion of 6 in DMSO (162 μL, 0.434 μmol) was diluted with
DMSO (160 μL), and DIEA (10.0 μL, 57.4 μmol) was
added to this stirred solution. Subsequently, a 44.1 mM
solution of DITC-APEC 2 in DMSO (450 μL, 19.8 μmol)
was slowly added to this stirred mixture. The reaction was
stirred for 7 days protected from light, purified by SEC (H
36.5 cm×O.D. 4.5 cm) in DMF, and dried in vacuo to give
13 as a white glassy solid.
1H NMR peak assignments were
made analogous to the labeling method shown for 10
previously.
1H NMR (600 MHz, DMSO-d6) δ 7.35, 7.32
(br s (each), 108.57H, H13 and H14), 7.14, 7.10 (d (each),
114.32H, J=7.7 Hz, H4 and H5), 6.80 (br s, 48.57H, H6Ad),
6.19 (s, 22.97H, H1), 5.84 (d, 25.63H, J=7.2 Hz, H1′), 5.64,
5.58 [br s (each), 48.16H, H3′-OH and H2′-OH], 4.72
(m, 26.09H, H2′), 4.26 (s, 27.57H, H4′), 4.19 (s, 31.08H,
H3′), 2.35 (m, 76.95H, H7), 2.20 (m, 120.00H, Hc), 0.96
(t, 86.75H, J=6.9 Hz, H18).
Radioligand membrane binding experiments Radioligand
binding assays were performed for A1,A 2A, and A3 ARs as
described [23]. Each tube in the binding assay contained
100 μL of membrane suspension (20 μg of protein), 50 μL
of agonist radioligand, and 50 μL of increasing concen-
trations of the test ligands in Tris-HCl buffer (50 mM, pH
7.5) containing 10 mM MgCl2. For the initial dissolution,
the dendrimer conjugate was heated in the buffer (80°C for
1 h). Nonspecific binding was determined using 10 μM5 ′-
N-ethylcarboxamidoadenosine diluted with the buffer. The
mixtures were incubated at 25°C for 60 min. Binding
reactions were terminated by filtration through Whatman
GF/B filters under reduced pressure using a MT-24 cell
harvester (Brandell, Gaithersburg, MD). Filters were
washed three times with 5 mL of 50 mM ice-cold Tris-
HCl buffer (pH 7.5). For A3 AR, the agonist radioligand
[
125I]N
6-(4-amino-3-iodobenzyl)adenosine-5′-N-methyluro-
namide (0.5 nM) was used. After the filters were washed,
the radioactivity was measured using a Beckman γ-counter.
For the A1 and A2A assays, the radioactive agonists [
3H]2-
chloro-N
6-cyclopentyladenosine and [
3H]2-(4-(2-carbox-
yethyl)phenylethylamino)-5′-N-ethylcarboxamido-adeno-
sine were used, respectively. After the filters were washed,
they were placed in scintillation vials containing 5 mL of
Hydrofluor scintillation buffer and counted using a Perkin
Elmer liquid scintillation counter. The Ki values were
determined using Prism (GraphPad) for all assays.
Measurement of functional AR activity An assay of cyclic
AMP accumulation in response to activation of the human
A2A AR expressed in CHO cells was performed as reported
[24].
CHO cells stably expressing the human A3 receptor were
grown in Dulbecco’s Modified Eagle Medium/F12 (Sigma)
supplemented with 10% fetal bovine serum, antibiotics, and
glutamine. Each assay was completed by passaging the
CHO A3 cells into 96-well plates and incubating overnight
at 37°C with 5% CO2. The FLIPR Calcium 4 Kit provided
by Molecular Devices was used as described previously
[25]. Briefly, the media was removed from the cells, and
30 μL of the Calcium 4 fluorescent dye supplemented with
2.5 mM probenecid was added to each well. The cells were
incubated at room temperature for 45 min. The plate was
prepared by diluting each compound to 10
−5 to 10
−9 Mi n
Hanks Buffer. Samples were run in duplicate on the
Molecular Devices FlexStation I at room temperature.
Cellular fluorescence (excitation at 485 nm; emission at
525 nm) was monitored following exposure to the
compound. Increases in the intracellular calcium level were
reported as the relative fluorescence intensity after the
exposure subtracting the basal fluorescence value before the
exposure. Each experiment was repeated at least three
times. The EC50 value for each compound was calculated
using Prism (GraphPad).
Preparation of human washed platelets Human washed
platelets were prepared as previously described [26].
Briefly, fresh blood obtained from healthy donors was
centrifuged at 175×g for 15 min at 37°C. Platelet-rich
plasma was removed and centrifuged at 1,570×g for 15 min
at 37°C. The platelet pellet was washed twice in Tyrode’s
buffer (137 mM NaCl, 2 mM KCl, 12 mM NaHCO3,
0.3 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 5.5 mM
glucose, 5 mM Hepes, pH 7.3) containing 0.35% human
serum albumin, and finally resuspended at a density of 3×
10
5 platelets/μL in the same buffer in the presence of
0.02 U/mL of the ADP scavenger apyrase (adenosine 5′-
triphosphate diphosphohydrolase, EC 3.6.1.5), a concentra-
tion sufficient to prevent desensitization of platelet ADP
receptors during storage. Platelets were kept at 37°C
throughout all experiments.
Platelet aggregation studies Aggregation was measured at
37°C by a turbidimetric method in a dual-channel Payton
aggregometer (Payton Associates, Scarborough, Ontario,
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stirred at 1,100 rpm and activated by addition of ADP in the
presence or absence of the dendrimer derivative and in the
presence of human fibrinogen (0.8 mg/mL) in a final
volume of 500 μL. The extent of aggregation was estimated
quantitatively by measuring the maximum curve height
above baseline level. For the antagonist experiment,
platelets were incubated with the potent and selective A2A
AR antagonist SCH442416 (10 μM) for 5 min, or with 10
(1 μM) for 5 min, or with SCH442416 (10 μM) (5 min)
followed by 10 (5 min), and then stimulated with ADP
5 μM.
Fluorescent confocal microscopy analysis Human washed
platelets (3×10
5 platelets/μL )r e s u s p e n d e di nT y r o d e ’s
buffer containing 0.35% albumin were incubated for
increasing periods of time (5, 15, 30, or 60 min) with
the dendrimer (as a DMSO solution) or with pure DMSO.
Platelets were then washed, resuspended in the same
buffer and fixed with paraformaldehyde 2%. Platelets
were then seeded on poly-L-lysine-coated glass cover-
slips. After washing, the coverslips were mounted in
Mowiol 4–88 and examined under a Leica laser confocal
scanning microscope (Leica SP5) equipped with a planar
apo oil immersion lens (×63, n.a.=1.4, or ×100, n.a.=
1.3).
Results and discussion
Our strategy for the development of dendrimer-based
macromolecular signaling agents began by first preparing
a monomeric analogue 3 that closely mimics the dendrimer-
attached form of DITC-APEC (Scheme 1). This structural
analogue served as a monomeric control for comparison to
the dendrimer conjugates in pharmacological assays. DITC-
APEC 2 [20] possesses a reactive isothiocyanate terminus,
which will readily react with any free amino or thiol
groups, including those on proteins, to form a covalent
linkage. Therefore, we chose an ethylenediamine (ED)—
similar to the PAMAM periphery—capped with an acetyl
group on one end to react with DITC-APEC 2 and to
convert to the neutral analogue 3. The
1H NMR peaks of 3
were fully assigned (Fig. S1B, Supporting Information)
with the aid of 2D COSY and NOESY experiments, which
were later used to easily distinguish the spectral peaks of its
dendrimer conjugates and to determine the stoichiometry of
ligand attachment by integration.
Recently, we reported on the preparation of G3 PAMAM
dendrimer conjugates loaded with multiple copies of
CGS21680 and observed the agonistic effects at the human
A2A AR to inhibit platelet aggregation [17]. APEC is
reported to have a higher binding affinity than CGS21680
at the human A2A AR, despite its known nonselectivity
between human A2A and A3 ARs [14]. In order to better
predict and compare the effects of these ligands following
covalent attachment to the dendrimer surface, a similar
analogue of CGS21680, 5, was prepared through a PyBOP-
mediated amide coupling (Scheme 2).
Next, DITC-APEC units were attached to the G3
PAMAM dendrimers (Scheme 3). Our design principle for
dendrimer conjugates involved: (1) preparation of conju-
gates with both low- and high-loading of DITC-APEC, (2)
attachment of a fluorophore, and (3) application of surface
modification of residual amines by acetylation in den-
drimers having a low degree of DITC-APEC substitution.
Despite the facile conjugation chemistry for the attachment
of various peripheral groups and their popularity as
potential gene delivery vehicles, amine-terminated
PAMAM dendrimers are known to be significantly toxic
in biological applications [27–29]. Partial acetylation can
Scheme 1 Synthesis of a DITC-APEC derivative 3 as a monomeric control
44 Purinergic Signalling (2009) 5:39–50both reduce toxicity [30, 31] and enhance the water-
solubility of PAMAM dendrimers loaded with various
pendant groups [32, 33]. Accordingly, we prepared the
dendrimer conjugate 10 with a low degree of DITC-APEC
substitution starting from the partially acetylated dendrimer
7, which was estimated to contain 14 acetamide groups out
of 32 available peripheral amino groups by NMR analysis
[22]. To a known concentration of 7 in DMSO, an
equimolar amount of fluorescein 5-carboxysuccinimide
ester was added to yield dendrimer 9. Estimation of the
degree of fluorescein substitution by the
1H NMR integra-
tion method was not practical due to the relatively low
signal intensity compared to the intensity of the PAMAM
dendrimer peaks. Thus, on average one equivalent of
fluorescein was assumed to be attached to each dendrimer
molecule. To this DMSO solution of 9, ca. nine equivalents
of DITC-APEC 2 were added. The mixture was stirred for
5–7 days and passed through an SEC column (exclusion
limit: 14,000 Da) with DMF as an eluent to collect a pure
dendrimer conjugate.
Subsequently, the degree of APEC attachment to the
dendrimer was determined by the
1H NMR integration
(Fig. S2, Supporting Information). Based on experimental
evidence [22], we assumed commercial G3 PAMAM
dendrimer 6 to have ca. 32 peripheral groups without any
major defects in the structure. Thus, a baseline-separated
1H
NMR peak corresponding to a recurring PAMAM methy-
lene near 2.20 ppm (“c”, see “Materials and methods” for
labeling) was used as an internal standard (120H), and the
relative integration value of a methyl peak at 0.96 ppm
(ribose 5′ substitution) was measured. On average, five
APEC groups were found to be attached to the dendrimer
conjugate through this integration method. Alternatively,
quantification of ligand substitution by comparing the
Scheme 2 Synthesis of a
CGS21680 derivative 5 as a
monomeric control
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was attempted. Unfortunately, obtaining a reliable UV
absorption was difficult due to the limited water-solubility,
significant overlap of the adenine and other aromatic
absorptions, and the high background absorption near the
aromatic region (260–290 nm) when using DMSO as a
solvent.
Similarly, dendrimer conjugates with a high degree of
DITC-APEC substitution were prepared (Scheme 4). Excess
amount of DITC-APEC 2 was added to either the fluo-
rescently labeled G3 PAMAM 11 or nonfluorescent
PAMAM 6. Characterization of the SEC-purified conjugates
12 and 13 by
1H NMR was achieved analogously to that for
10 to have 31 and 29 DITC-APEC attachments, respectively
(Figs. S3 and S4, Supporting Information). Interestingly,
later we consistently found that all three PAMAM conjugates
—10, 12,a n d13—slowly degraded and lost some of the
covalently attached APEC content when repurified by SEC
and analyzed by
1H NMR. The degree of decomposition was
the highest for dendrimer 10 which had the lowest ligand
substitution. Currently, the mechanism of degradation of the
APEC linkage is not fully elucidated; however, the basic
amino groups of the PAMAM scaffold likely participate in
this unexpected bond cleavage. One possible explanation can
be a base-catalyzed degradation of the partially conjugated
aromatic bisthiourea moiety to produce aniline and hydro-
lyzed products of the isothiocyanate groups on either side.
1
The size of these dendrimer conjugates was estimated by
computer modeling (Fig. 1, HyperChem 7.5.2, Amber force
field). The energy-minimized structure of G3 PAMAM with
full DITC-APEC substitutions (i.e., 32 ligands) suggested
an overall diameter of ca. 80–110 Å with a somewhat
ellipsoidal shape [34], similar to the CGS21680 conjugate
reported previously [17]. The extension of diameter by ca.
20 Å for the DITC-APEC dendrimer conjugate compared to
the CGS21680 dendrimer analogue may afford enhanced
conformational flexibility of the linker arms to reach out
and benefit in the potential multivalent ligand-receptor
interactions. Indeed, this extension of dendrimer diameter
closely matched twice the difference of the linker distance
predicted by the energy-minimization (PM3) carried out for
the fully stretched forms of the monomeric controls 3 and 5
(Fig. S5, Supporting Information).
In vitro binding and functional assays at human ARs were
then performed using the nucleoside-dendrimer conjugates
10, 12,a n d13 (Table 1). Three subtypes of human ARs—
A1,A 2A,a n dA 3—were stably expressed in either CHO or
HEK-293 cells. Functional assays of the stimulation of
adenylate cyclase via the A2A AR and calcium mobilization
via the A3 AR were also performed. Several related
monomers, APEC 1, a monomeric control 3 derived from
DITC-APEC, CGS21680 4, and a monomeric control 5
derived from CGS21680, were also assayed under the same
conditions. First, the monomers were compared for their
binding at these three subtypes of ARs. Except for the APEC
1, which showed a moderate effect, the three monomers—3,
4,a n d5—did not exhibit any significant binding at the A1
AR. APEC, the highest affinity binder at the A2A AR, had a
diminished effect when its distal amino group was either
acetylated to form 5 or substituted with an end-capped
1 Independently, when a monomeric analogue of 3 capped with a Boc
group (structure not shown) was treated with trifluoroacetic acid, a
molecular ion corresponding to the mass of the APEC derivative with
the isothiocyanate end group instead of amine was found exclusively
in the mass spectrum (Kim Y, Jacobson KA, unpublished results).
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at the A2A AR for CGS21680 4 lacking the ED unit was
similar to the value obtained for 3; however, the end-capped
CGS21680 monomeric control 5 with an ED extension
exhibited the lowest affinity. Nonetheless, activation of
adenylate cyclase, characteristic of A2A AR agonists, by
CGS21680 analogue 5 was achieved at a comparable degree
to that by CGS21680 4. Here, the chemical structure of the
CGS21680 monomeric control 5 closely resembles that of
APEC 1 except for its distal amino group being capped by
an acetyl group. Accordingly, the free amino group of APEC
1 may be the key element in achieving the high binding
affinity and potencyat the A2A AR. For A3 AR, despite the
limited available comparisons, APEC 1 showed the highest
binding affinity and potency. The binding affinity of APEC
at the A3 AR was comparable to that at the A2A AR, as
reported [14]. The monomeric control 5 derived from
CGS21680, which best resembles the structure of APEC
but with the end-capping, also displayed a relatively strong
affinity at the human A3 AR. However, CGS21680 4 without
the ED extension had a significantly lower affinity, suggest-
ing the importance of the ED unit for the A3 AR recognition.
Intriguingly, the actual agonistic effect of CGS21680 control
5 at the A3 AR, measured by the increase in the intracellular
calcium concentration, was substantially weaker when
compared to that of APEC 1.
Next, the binding affinities of dendrimers at three
subtypes of human ARs were determined. The commercial
PAMAM dendrimer 6 without any ligand attachments did
not show any detectable binding effect at all three ARs
tested. Interestingly, the fluorescent dendrimer 9—precur-
sor of 10—without any ligand slightly inhibited binding at
the A3 AR, but there were no effects at the other AR
subtypes. The binding at A1 AR of all tested dendrimers
was negligible. The reduction of nucleoside ligand affinity
at the A1 AR upon its conjugation to the dendrimers
indicates an increased preference for the other two
receptors, A2A and A3 ARs. Here, the difference in the
effects exhibited between dendrimers with high- and low-
loading of APEC ligands was minor (i.e., within experi-
mental error). Overall, when compared to the monomeric
ligands (e.g., DITC-APEC control 3), attachment of APEC
derivatives to PAMAM dendrimer slightly reduced the
affinity at A2A AR while preserving the binding affinity at
the A3 AR. As suggested previously by comparing the
monomers, the distal amino group of APEC, which is
lacking in the dendrimer-appended form, may be crucial in
achieving a potent effect at the A2A AR. On the other hand,
affinity of the APEC derivatives at the A3 AR, which may
be improved by the addition of an ED moiety, was not
affected by attaching them to the dendrimers. Taken
together, the attachment of APEC derivatives to the
periphery of a G3 PAMAM dendrimer through an extended
linker with a dithioureylenephenyl functionality, may have
slightly improved the relative affinity at the A3 AR
compared to A2A AR. Yet, the water-solubility of den-
drimer conjugates, especially with high-loading of APEC
derivatives 12 and 13 was relatively low, and further
Fig. 1 An energy-minimized structure of a G3-PAMAM dendrimer
conjugate having 32 covalently bound DITC-APEC groups (right,
analogue of 13). The calculation proceeded using the HyperChem
7.5.2 software through an Amber force field. Terminal adenosine
moieties are highlighted in pink for visibility. Overall diameters, ca.
80–110 Å, were measured (shown in green) between ligands (C3′-C3′
distance of the ribose ring) approximately diagonal to each other
through the central core
Purinergic Signalling (2009) 5:39–50 47improvements in the structural design of our dendritic
nanocarrier are necessary for a more accurate evaluation.
To determine the agonistic effects of our fluorescent
dendrimer conjugates at the A2A AR, we then examined their
a n t i a g g r e g a t o r ye f f e c to np l a t e l e ta g g r e g a t i o n[ 35]. Adeno-
sine and synthetic agonists of the A2A AR inhibit ADP-
induced platelet aggregation. In addition, our previous
PAMAM dendrimer conjugate loaded with multiple copies
of CGS21680 also manifested an efficient antiaggregatory
effect through the activation of A2A AR [17]. Here, three
fluorescent dendrimers—9, 10,a n d12—were subjected to in
vitro aggregometry using human washed platelets (Fig. 2).
Dendrimer 9, which did not contain any APEC derivatives,
served as a control. As anticipated, an efficient antiaggrega-
tory effect was observed when the platelets were incubated
with each of the dendrimer conjugates 10 or 12,f o l l o w e db y
stimulation with ADP to initiate platelet aggregation. Neither
the dendrimer control 9, which contained no covalently
attached nucleoside, nor a DMSO control inhibited platelet
aggregation. A selective antagonist of the A2A AR,
SCH442416 [36], was used to demonstrate that the inhibition
of platelet aggregation by dendrimer 10 occurred through the
activation of the A2A AR. Preapplication of SCH442416
(10 μM) had no effect on aggregation induced by 5 μM
ADP, while it completely reversed the inhibitory effect of 1
µM 10 (data not shown).
Interestingly, an efficient internalization into the platelets
was detected by fluorescent confocal microscopy only for
Table 1 Radioligand binding (Ki) results of monomers and dendrimer derivatives at three subtypes of human ARs and functional (EC50) assay
results (stimulation of adenylate cyclase via the A2A AR and calcium mobilization via the A3 AR)
a
Compound Composition Ki (nM) EC50 (nM)
hA1 hA2A hA3 hA2A hA3
Monomer
1 APEC 168±36 29±5 38±11 8.2±1.7 170±90
3 N-Ac-ED-DITC-APEC 840±100 70±3 n.d. n.d. 375±40
4 CGS21680 5,780±590 67±19 247±79 53±16 n.d.
5 N-Ac-ED-CGS21680 984±223 110±15 58±24 51±8 725±110
Dendrimer
b
xy z
6 0 0 0 n.a. n.a. n.a. n.d. n.d.
9 14 1 0 n.a. n.a. (52±2)%
c n.d. n.d.
10 14 1 5 (36±13)%
c 152±31 42±5 n.d. n.d.
12 0 1 31 (32±20)%
c 96±20 55±22 n.d. n.d.
13 0 0 29 (44±13)%
c 130±16 69±26 n.d. n.d.
n.d. Not determined, i.e., binding (or functional) experiment was not conducted, n.a. not active, i.e., no binding was detected at ≤10 μM
aValues are presented as the mean ± SEM of three or more independent experiments. A1 and A3 ARs were expressed in CHO cells and A2A AR in
HEK-293 cells. Ki values are reported for the binding assay, and EC50 values are reported for the functional assay
bPAMAM dendrimer 6 was assumed to have 32 peripheral amino groups without any defects in the structure. Number of peripheral attachments
(x for acetamide groups, z for nucleoside units) was determined by the analysis of
1H NMR integration. Number of fluorescein groups (y) was
estimated based on the molar equivalents added to the reaction
cMeasured as percent inhibition at 10 μM
48 Purinergic Signalling (2009) 5:39–50the control dendrimer 9 (Fig. 3). Other PAMAM dendrimer
conjugates, 10 and 12, bearing APEC derivatives, were not
detectably internalized. The fluorescence intensity of
fluorescein derivatives is pH-dependent, and thus may be
subject to intracellular inactivation, which may affect these
results. Indeed, under a confocal microscope, multiple
numbers of the individual fluorescent dendrimer molecule
9 were found inside each platelet. Thus, present findings do
not support that the internalization of these dendrimer
derivatives is AR-mediated, because only the control
dendrimer was internalized.
Conclusions
New dendrimer-based macromolecular therapeutics for
GPCRs were prepared by treating the surface amino groups
of G3 PAMAM dendrimers with different molar ratios of
DITC-APEC, a chemically reactive A2A AR agonist. The
present study expanded our previous efforts to engineer a
similar A2A AR-specific dendritic nanocarrier, an amide-
linked PAMAM-CGS21680 conjugate that retained biolog-
ical activity. Compared to the CGS21680 dendrimer con-
jugates, our new dendritic delivery agents described herein
aimed to enhance: (1) the conformational flexibility to
achieve a favorable geometry for binding at the heptahelical
domain of ARs, and (2) the specificity in binding by the
added dithioureylenephenyl functionality at the distal unit
under the scheme of functionalized congener approach.
Affinities of submicromolar Ki values were obtained from
the PAMAM-DITC-APEC conjugates at A2A ARs; however,
the selectivity at A3 AR slightly increased with regard to the
binding profile of small molecule monomers. Furthermore,
these PAMAM dendrimers loaded with APEC derivatives
displayed an efficient inhibitory effect on platelet aggrega-
tion stimulated by ADP, which is characteristic of A2A AR
agonists. Thus, application of dendrimer technology to the
A2A AR might lead to novel antithrombotic agents.
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Fig. 2 Platelet aggregation studies at 37°C in the presence or absence
of dendrimers. A suspension of human washed platelets was incubated
for increasing periods of time with DMSO (control) or dendrimers
(each dendrimer was added as a DMSO solution), to which ADP was
then added to induce platelet aggregation. Each dendrimer was added
as a DMSO solution (5 mM) and the final concentration of dendrimers
in the media was 1 μM (500 μL). The total content of DMSO in the
media was 0.02% (v/v) in all cases. The control was prepared
similarly from the DMSO solution without any dendrimer
20 µm 5 µm zoomed
one single
platelet
Fig. 3 Fluorescence confocal
microscopy of human washed
platelets incubated with either
dendrimer 9 (1 μM) for 5 min.
The fluorescent dendrimer 9
internalized into the platelet is
shown as green dots. The total
content of DMSO in the media
was 0.02% (v/v)
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